vs ibrutinib

Be among the first to discover the new data from the head-to-head trial of CALQUENCE vs ibrutinib

*Required fields

Thank you for signing up for more information

The information you submit will be governed by our Privacy Notice.

Indication and Usage

Indication and Usage

CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Select Safety Information

Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, and atrial fibrillation and flutter. The most common adverse reactions (≥ 30%) of any grade in patients with CLL were anemia, neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea.

Please see full Prescribing Information, including Patient Information.